Drop biologic suffixes IGBA urges US FDA

Additional identifiers such as suffixes to international non-proprietary names (INNs) are not needed for successful traceability and identification of biological drugs, the International Generic and Biosimilar Medicines Association (IGBA) argues in an updated position. “No data exists to demonstrate that added non-memorable suffixes in the US will improve the US pharmacovigilance system,” the international trade body has stressed ahead of a US Food and Drug Administration (FDA) public hearing on “facilitating price competition and innovation in the biological products marketplace” to be held on 4 September (Generics bulletin, 3 August 2018, page 9).

Additional identifiers such as suffixes to international non-proprietary names (INNs) are not needed for successful traceability and identification of biological drugs, the International Generic and Biosimilar Medicines Association (IGBA) argues in an updated position. “No data exists to demonstrate that added non-memorable suffixes in the US will improve the US pharmacovigilance system,” the international trade body has stressed ahead of a US Food and Drug Administration (FDA) public hearing on “facilitating price competition and innovation in the biological products marketplace” to be held on 4 September (Generics bulletin, 3 August 2018, page 9).

“Many currently licensed originator biologics in the US have shared non-proprietary names for decades with no pharmacovigilance concerns,” the IGBA...

More from Regulation

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By 

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

 

Generics Bulletin reviews global regulatory developments across the world.

Generic Drug Office’s Policy Staff Returning To US FDA

 

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

More from Policy & Regulation

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

 

Generics Bulletin reviews global regulatory developments across the world.

Generic Drug Office’s Policy Staff Returning To US FDA

 

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

US ‘Red Tape’ Bill Again Targets Biosimilar Interchangeability – Will It Succeed This Time?

 
• By 

After multiple past attempts, US legislators have once again proposed a bill that would make all biosimilars immediately interchangeable upon approval. Could a fresh political context help it to succeed this time?